Labo Euromedis (FRA:61R) Total Equity: €16.41 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:61R Labo Euromedis FRA:61R
61 GF Score
Price €4.76
GF Value €4.37
! 6 Warning Signs
View Full Analysis

What is Labo Euromedis Total Equity?

Labo Euromedis FRA:61R +0.42% 61 Total Equity is €16.41 Mil as of Dec. 2025. GuruFocus rates FRA:61R with a GF Score™ of 61/100 and a GF Value™ of €4.37. The stock has 6 warning signs investors should review.

Labo Euromedis's total equity for the quarter that ended in Dec. 2025 was €16.41 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Labo Euromedis Total Equity Historical Data

* Premium members only.

The historical data trend for Labo Euromedis's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labo Euromedis Total Equity Chart

Labo Euromedis Annual Data
Trend Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.24 34.88 22.59 16.48 16.41

Labo Euromedis Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.59 22.06 16.48 16.58 16.41
FRA:61R
61GF Score
Labo Euromedis FRA:61R
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labo Euromedis Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Labo Euromedis's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=39.493-23.084
=16.41

Labo Euromedis's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=39.493-23.084
=16.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €16.41 Mil mean?
Labo Euromedis (FRA:61R) has a Total Equity of €16.41 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Labo Euromedis and its competitors.
Is Labo Euromedis' Total Equity too high?
Labo Euromedis' current Total Equity is €16.41 Mil. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Total Equity compare to MCK and CAH?
Labo Euromedis' Total Equity of €16.41 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Distribution company?
A good Total Equity depends on the Medical Distribution industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Labo Euromedis and its competitors. Labo Euromedis's current Total Equity is €16.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Total Equity of €16.41 Mil. The stock's GF Value™ is €4.37, compared to a current price of €4.76 — trading 8.9% above its estimated fair value. The current Total Equity is €16.41 Mil. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Total Equity is €16.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labo Euromedis (FRA:61R) Overvalued in 2026?

Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued. The current stock price of €4.76 is trading 8.9% above its estimated GF Value™ of €4.37.

Key valuation signals for FRA:61R:

  • Total Equity: €16.41 Mil
  • GF Value™: €4.37 vs. price of €4.76 (8.9% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labo Euromedis Business Description

Address ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score

Get the complete analysis for FRA:61R

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.76
Price
€4.37
GF Value